Search

Now showing items 1-10 of 12

Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest

Girard, P. M.; Campbell, T. B.; Grinsztejn, Beatriz; Hartikainen, J.; Rachline, A.; Nijs, S.; Witek, J. (2012)

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

Katlama, Christine; Clotet, Bonaventura; Mills, Anthony; Trottier, Benoit; Molina, Jean-Michel; Grinsztejn, Beatriz; Towner, William; Haubrich, Richard; Nijs, Steven; Vingerhoets, Johan; Woodfall, Brian; Witek, James (2010)

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

Katlama, Christine; Haubrich, Richard; Lalezari, Jacob; Lazzarin, Adriano; Madruga, José V; Molina, Jean-Michel; Schechter, Mauro; Peeters, Monika; Picchio, Gaston; Vingerhoets, Johan; Woodfall, Brian; De Smedt, Goedele; DUET-1 study group; DUET-2 study group (Wolters Kluwer Health | Lippincott Williams & Wilkins, 2018)

Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest

Girard, P. M.; Campbell, T. B.; Grinsztejn, Beatriz; Hartikainen, J.; Rachline, A.; Nijs, S.; Witek, J. (2018)

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

Madruga, José Valdez Ramalho; Cahn, Pedro; Grinsztejn, Beatriz; Haubrich, Richard; Lalezari, Jacob; Mills, Anthony; Pialoux, Gilles; Wilkin, Timothy; Peeters, Monika; Vingerhoets, Johan; de Smedt, Goedele; Leopold, Lorant; Trefiglio, Roberta; Woodfall, Brian; DUET-1 study group (Elsevier, 2007)

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

The cursed duet today: Tuberculosis and HIV-coinfection

Tiberi, Simon; Carvalho, Anna Cristina C.; Sulis, Giorgia; Vaghela, Devan; Rendon, Adrian; Mello, Fernanda C. de Q.; Rahman, Ananna; Matin, Nashaba; Zumla, Ali; Pontali, Emanuele (Elsevier Masson, 2017)

Search

Filters

Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

The cursed duet today: Tuberculosis and HIV-coinfection

The cursed duet today: Tuberculosis and HIV-coinfection